The National Home Infusion Foundation’s (NHIF) Status at Discharge Benchmarking initiative is based on the need for research that evaluates the safety of home infusion services and aims to understand why patients discontinue their home infusion service.
On Tuesday, September 19, 2023, the House Energy & Commerce Health Subcommittee held a legislative hearing, “Examining Policies to Improve Seniors’ Access to Innovative Drugs, Medical Devices, and Technology.” Home infusion was discussed at least 3 distinct times throughout the hearing, with a consensus that Medicare needs to improve beneficiary access to home infusion services.
NHIA submitted comments on a CMS PFS proposed rule (CMS-1784-P) that would affect Medicare classification and coverage of self-administered drugs, certain biologics and coding and billing requirements related to the use of single dose containers and drug waste.
NHIA responded to an FDA request for comment on “Increasing Patient Access to At-Home Use Medical Technologies,” applauding the agency for recognizing the importance of facilitating access to care in the home.
NHIA submitted comments to CMS on the proposed 2024 home health payment rule. CMS did not mention the HIT services benefit in its 2024 rulemaking, however, NHIA believes it is important to continue advocating on behalf of Medicare beneficiaries to improve access to home infusion services.
On Friday June 30, 2023, CMS released proposed updates to the Medicare Home Health Prospective Payment System for CY 2024. The proposed home health rule does not address home infusion therapy (HIT) services other than to describe the potential interaction with the new Home IVIG Items and Service benefit, which replaces the IVIG demonstration starting on January 1, 2024.
The National Home Infusion Association (NHIA) applaudes the introduction of bipartisan legislation in the U.S. Senate that will ensure Medicare patients can receive the intravenous (IV) medications they need while at home.
The National Home Infusion Association (NHIA) is pleased to hold its second annual one-day Payor Summit. The event, designed to bring together representatives from commercial health insurance plans with home and specialty infusion leaders, will take place August 23, 2023 in Dallas, TX.
NHIA applauds the guidance issued by FDA to allow for decentralized clinical trials, including in patients’ homes. NHIA believes that allowing decentralized clinical trials will improve the representation in trials. According to the FDA guidance, “remote clinical trial visits and clinical trial-related activities are important strategies to make trials more convenient and more accessible” and “sponsors should strive for diversity and inclusiveness in trial populations.”
The National Home Infusion Association (NHIA) applauds the introduction of the “Expanding Care in the Home Act,” (H.R.2853) which would expand coverage for home-based services, such as home infusion, dialysis, diagnostic imaging, and personal care services for Medicare beneficiaries.
Last week concluded the 2023 National Home Infusion Association (NHIA) Annual Conference, which brings together nearly 1,500 home and alternate site infusion professionals for four days of networking, education, and expo. This year’s event saw significant growth in attendance over prior years and the expo featured more than 125 companies displaying the latest products and services supporting the industry.
Eliminating the inequities in how people access and receive health care can go a long way toward improving health care delivery, outcomes, and population health, according to Christina Ritchey from Optum Infusion Pharmacy. Equity in health care means the state in which everyone has a fair and just opportunity to attain their highest level of health.
Attendees gathered for a morning coffee break after an engaging breakfast symposium from IgNS on PANS/PANDAS in Children. The beautiful backdrop overlooking the Potomac played host to some excellent conversations among professionals as everyone fueled up for a jam-packed day of education.
As we enter the third year since the global pandemic and a return to “normal,” you might expect that trauma and anxiety related to the crisis would be waning. In fact, the opposite is true, according to Alissa Putman, PhD with Johns Hopkins Community Physicians. In 2022, 65% of psychologists reported an increase in symptom severity, including stress, anxiety, and depression. All of which can affect health care’s most precious resource: its workers.
With record attendance and beautiful spring weather in D.C., we had a full first day of action at NHIA 2023, starting off early with our three preconference seminars: Executive, Sterile Compounding and Revenue Cycle, covering valuable information for professionals in a variety of roles.
The National Home Infusion Association has announced the finalists for its 2023 Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
The National Home Infusion Association (NHIA) is pleased to announce that it successfully petitioned the Centers for Medicare and Medicaid Services (CMS) to secure a new billing code for injectable immunotherapies and revise an existing code to facilitate administration of a wider range of monoclonal antibodies for Respiratory Syncytial Virus (RSV).
The National Home Infusion Foundation’s (NHIF) Status at Discharge Benchmarking initiative is based on the need for research that evaluates the safety of home infusion services and aims to understand why patients discontinue their home infusion service.
On Tuesday, September 19, 2023, the House Energy & Commerce Health Subcommittee held a legislative hearing, “Examining Policies to Improve Seniors’ Access to Innovative Drugs, Medical Devices, and Technology.” Home infusion was discussed at least 3 distinct times throughout the hearing, with a consensus that Medicare needs to improve beneficiary access to home infusion services.
NHIA submitted comments on a CMS PFS proposed rule (CMS-1784-P) that would affect Medicare classification and coverage of self-administered drugs, certain biologics and coding and billing requirements related to the use of single dose containers and drug waste.
NHIA responded to an FDA request for comment on “Increasing Patient Access to At-Home Use Medical Technologies,” applauding the agency for recognizing the importance of facilitating access to care in the home.
NHIA submitted comments to CMS on the proposed 2024 home health payment rule. CMS did not mention the HIT services benefit in its 2024 rulemaking, however, NHIA believes it is important to continue advocating on behalf of Medicare beneficiaries to improve access to home infusion services.
On Friday June 30, 2023, CMS released proposed updates to the Medicare Home Health Prospective Payment System for CY 2024. The proposed home health rule does not address home infusion therapy (HIT) services other than to describe the potential interaction with the new Home IVIG Items and Service benefit, which replaces the IVIG demonstration starting on January 1, 2024.
The National Home Infusion Association (NHIA) applaudes the introduction of bipartisan legislation in the U.S. Senate that will ensure Medicare patients can receive the intravenous (IV) medications they need while at home.
The National Home Infusion Association (NHIA) is pleased to hold its second annual one-day Payor Summit. The event, designed to bring together representatives from commercial health insurance plans with home and specialty infusion leaders, will take place August 23, 2023 in Dallas, TX.
NHIA applauds the guidance issued by FDA to allow for decentralized clinical trials, including in patients’ homes. NHIA believes that allowing decentralized clinical trials will improve the representation in trials. According to the FDA guidance, “remote clinical trial visits and clinical trial-related activities are important strategies to make trials more convenient and more accessible” and “sponsors should strive for diversity and inclusiveness in trial populations.”
The National Home Infusion Association (NHIA) applauds the introduction of the “Expanding Care in the Home Act,” (H.R.2853) which would expand coverage for home-based services, such as home infusion, dialysis, diagnostic imaging, and personal care services for Medicare beneficiaries.
Last week concluded the 2023 National Home Infusion Association (NHIA) Annual Conference, which brings together nearly 1,500 home and alternate site infusion professionals for four days of networking, education, and expo. This year’s event saw significant growth in attendance over prior years and the expo featured more than 125 companies displaying the latest products and services supporting the industry.
Eliminating the inequities in how people access and receive health care can go a long way toward improving health care delivery, outcomes, and population health, according to Christina Ritchey from Optum Infusion Pharmacy. Equity in health care means the state in which everyone has a fair and just opportunity to attain their highest level of health.
Attendees gathered for a morning coffee break after an engaging breakfast symposium from IgNS on PANS/PANDAS in Children. The beautiful backdrop overlooking the Potomac played host to some excellent conversations among professionals as everyone fueled up for a jam-packed day of education.
As we enter the third year since the global pandemic and a return to “normal,” you might expect that trauma and anxiety related to the crisis would be waning. In fact, the opposite is true, according to Alissa Putman, PhD with Johns Hopkins Community Physicians. In 2022, 65% of psychologists reported an increase in symptom severity, including stress, anxiety, and depression. All of which can affect health care’s most precious resource: its workers.
With record attendance and beautiful spring weather in D.C., we had a full first day of action at NHIA 2023, starting off early with our three preconference seminars: Executive, Sterile Compounding and Revenue Cycle, covering valuable information for professionals in a variety of roles.
The National Home Infusion Association has announced the finalists for its 2023 Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
The National Home Infusion Association (NHIA) is pleased to announce that it successfully petitioned the Centers for Medicare and Medicaid Services (CMS) to secure a new billing code for injectable immunotherapies and revise an existing code to facilitate administration of a wider range of monoclonal antibodies for Respiratory Syncytial Virus (RSV).
